Pfizer (NYSE:PFE) Shares Down 1.7% - Here's Why

Key Points

• Pfizer shares fell about 1.7% midday to roughly $26.85 on lighter volume, despite beating Q4 estimates with $0.66 EPS (vs. $0.57) and $17.56 billion in revenue.
• Pipeline and regulatory positives include China approval of GLP‑1 weight‑management drug Xianweiying, strong Phase 2 trispecific eczema data for tilrekimig, and early‑stage oncology and vaccine milestones that could support longer‑term growth.
• Analysts are mixed (average rating "Hold", average target $28.05) and investors cite valuation and patent/legal risks; Pfizer pays a ~6.4% dividend yield but has a high payout ratio (~126%), which raises sustainability concerns.

Pfizer Inc. (NYSE:PFE - Get Free Report) shares fell 1.7% during mid-day trading on Thursday . The stock traded as low as $26.63 and last traded at $26.8450. 38,460,387 shares were traded during trading, a decline of 18% from the average session volume of 47,037,539 shares. The stock had previously closed at $27.30.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large addressable market and adding a recurring‑revenue opportunity outside the U.S./EU. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Strong Phase 2 trispecific eczema data for tilrekimig: the drug showed meaningful benefit vs. placebo and a favorable safety profile — if confirmed in later trials this could materially expand Pfizer’s immunology franchise and long‑term growth runway. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer launched an early‑stage oncology trial for PF‑07994525, extending its oncology pipeline — a constructive signal on R&D prioritization, though clinical upside is longer‑dated. Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline
• Positive Sentiment: Completed a Phase 2 toddler study for its next‑gen pneumococcal vaccine — another concrete pipeline milestone that supports future vaccine revenue potential. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
• Neutral Sentiment: Sector roundup/market talk noting moves at other healthcare names (Celltrion, Sanofi, Roche, etc.) — useful for context but not Pfizer‑specific. Health Care Roundup: Market Talk
• Neutral Sentiment: Pfizer commentary on handling regulatory uncertainty (ClinicalTrialsArena) — signals internal preparedness but unlikely to move shares materially in the near term. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Analyst/market pieces question Pfizer’s valuation and pipeline visibility ("Cheap For A Reason" / "Does Pfizer Offer Value") — renewed skepticism about post‑pandemic growth and patent cliffs can pressure the multiple and trigger profit‑taking. Pfizer: Cheap For A Reason
• Negative Sentiment: Patent/legal uncertainty in the sector (news of a patent shake‑up around tafamidis that moved competitors like BridgeBio) highlights IP risks and competitive dynamics that can weigh on Pfizer’s outlook for certain therapies. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up

Analyst Ratings Changes

PFE has been the subject of several analyst reports. Morgan Stanley reduced their target price on Pfizer from $32.00 to $28.00 and set an "equal weight" rating for the company in a report on Friday, December 12th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They set a "sector outperform" rating and a $30.00 price objective for the company. TD Cowen reiterated a "hold" rating on shares of Pfizer in a research note on Tuesday, December 30th. Finally, Barclays initiated coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an "underweight" rating and a $25.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $28.05.

Pfizer Stock Down 1.7%

The firm's 50-day simple moving average is $26.43 and its 200-day simple moving average is $25.50. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company has a market capitalization of $152.65 billion, a price-to-earnings ratio of 19.74 and a beta of 0.47.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the prior year, the business earned $0.63 earnings per share. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Friday, January 23rd were given a $0.43 dividend. The ex-dividend date was Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer's dividend payout ratio (DPR) is currently 126.47%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Brighton Jones LLC increased its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the period. United Bank grew its stake in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after purchasing an additional 6,415 shares during the period. ProShare Advisors LLC raised its holdings in shares of Pfizer by 10.6% in the 2nd quarter. ProShare Advisors LLC now owns 1,094,571 shares of the biopharmaceutical company's stock worth $26,532,000 after buying an additional 104,687 shares in the last quarter. Finally, Allworth Financial LP lifted its position in shares of Pfizer by 43.5% during the 2nd quarter. Allworth Financial LP now owns 218,449 shares of the biopharmaceutical company's stock worth $5,295,000 after buying an additional 66,209 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.